ArticleNature communications2023
Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Identification of Key Genes Related to SUMOylation and Potassium Channels and Their Mechanism of Influence on Pulmonary Arterial Hypertension.Biochemical genetics · 2026Article
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Survival Into Adulthood With FOXF1-Associated Pulmonary Vascular Disease After Neonatal Onset.Pulmonary circulation · 2026Article
- Molecular-Genetic Basis of Pulmonary Arterial Hypertension (PAH).Current issues in molecular biology · 2026Review
- Advances in the pathogenesis and clinical management of pulmonary hypertension.Medical review (2021) · 2026Review
- Identification and functional analysis of NADFrontiers in genetics · 2026Article
- Targeting Inflammation-Oxidative Stress Crosstalk: Advances and Challenges in Nanocarrier-Based Interventional Strategies for Pulmonary Arterial Hypertension.International journal of nanomedicine · 2026Review
- A second-hit conceptual framework for pulmonary arterial hypertension in adult congenital heart disease: genetics, hemodynamics, and treat-and-repair.Frontiers in cardiovascular medicine · 2026Review
- Long-term outcomes of Qing-Dai-induced pulmonary arterial hypertension.ERJ open research · 2025Article
- High Shear Stress Reduces ERG Causing Endothelial-Mesenchymal Transition and Pulmonary Arterial Hypertension.Arteriosclerosis, thrombosis, and vascular biology · 2025Article
- Magnesium ion hydrogel enhances resistance to radiation-induced bone injury by modulating the bone immune microenvironment and promoting microvascularization.Regenerative biomaterials · 2025Article
- Decoding the enigmatic estrogen paradox in pulmonary hypertension: delving into estrogen metabolites and metabolic enzymes.Cellular & molecular biology letters · 2024Review
- Pathology and pathobiology of pulmonary hypertension: current insights and future directions.The European respiratory journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 2 countries.
Sarasa IsobeBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-7405-0903
Ramesh V NairStanford Center for Genomics and Personalized Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Helen Y KangBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.
Lingli WangBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.
Jan-Renier MoonenBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.
Tsutomu ShinoharaBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.
Aiqin CaoBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.
Shalina TaylorVera Moulton Wall Center for Pulmonary Vascular Diseases, Stanford University, Stanford, CA, USA.
Shoichiro OtsukiVera Moulton Wall Center for Pulmonary Vascular Diseases, Stanford University, Stanford, CA, USA.ORCID 0000-0002-8379-8673
David P MarcianoStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Rebecca L HarperVera Moulton Wall Center for Pulmonary Vascular Diseases, Stanford University, Stanford, CA, USA.ORCID 0000-0003-1465-7372
Mir S AdilBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2129-1228
Chongyang ZhangBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.
Mauro Lago-DocampoBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-8799-6079
Jakob KörbelinDepartment of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-5435-7182
Jesse M EngreitzBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-5754-1719
Michael P SnyderStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0784-7987
Marlene RabinovitchBasic Science and Engineering (BASE) Initiative at the Betty Irene Moore Children's Heart Center, Lucile Packard Children's Hospital, Stanford University School of Medicine, Stanford, CA, USA. marlener@stanford.edu.ORCID 0000-0001-7886-7104
Lucile Packard Children's Hospital · USCardiovascular Institute of the South · USStanford Medicine · USUniversität Hamburg · DE
Funding
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2MThe Cellular Response to Elafin in PAHP01HL108797 · NHLBI · STANFORD UNIVERSITY · PI NOLAN, GARRY P · 2011 to 2021
$19.7MPulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1MThe BMP-PPARy Axis and Pulmonary HypertensionR01HL087118 · NHLBI · STANFORD UNIVERSITY · PI RABINOVITCH, MARLENE · 2008 to 2022
$7.2MStanford Training Program in Lung BiologyT32HL129970 · NHLBI · STANFORD UNIVERSITY · PI CORNFIELD, DAVID N., NICOLLS, MARK ROBERT · 2016 to 2025
$3.2MHigh Shear Stress Alters Gene Regulation in Pulmonary Arterial HypertensionR01HL152134 · NHLBI · STANFORD UNIVERSITY · PI RABINOVITCH, MARLENE · 2021 to 2024
$2.9MSystematic mapping and prediction of gene-enhancer connectionsR00HG009917 · NHGRI · STANFORD UNIVERSITY · PI ENGREITZ, JESSE M · 2020 to 2022
$796kTherapeutic Rescue of a Deficient BMPR2 Hypoxic Response in Pulmonary Arterial HypertensionR00HL145097 · NHLBI · FLORIDA INTERNATIONAL UNIVERSITY · PI MARCIANO, DAVID P · 2022 to 2024
$747kHigh-throughput sequencer for multi-scale genomic studiesS10OD020141 · OD · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2015 to 2015
$600kTherapeutic Rescue of a Deficient BMPR2 Hypoxic Response in Pulmonary Arterial HypertensionK99HL145097 · NHLBI · STANFORD UNIVERSITY · PI MARCIANO, DAVID P · 2019 to 2020
$221kSystematic mapping and prediction of gene-enhancer connectionsK99HG009917 · NHGRI · BROAD INSTITUTE, INC. · PI ENGREITZ, JESSE M · 2018 to 2019
$65kNCRR NIH HHS UL1 RR024986NHGRI NIH HHS K99 HG009917NHGRI NIH HHS R00 HG009917NHLBI NIH HHS K99 HL145097NHLBI NIH HHS P01 HL108797NHLBI NIH HHS R00 HL145097NHLBI NIH HHS R01 HL087118NHLBI NIH HHS R01 HL152134NHLBI NIH HHS R24 HL123767NHLBI NIH HHS T32 HL129970NIH HHS S10 OD020141
Abstract
Pulmonary arterial hypertension (PAH) is a progressive disease in which pulmonary arterial (PA) endothelial cell (EC) dysfunction is associated with unrepaired DNA damage. BMPR2 is the most common genetic cause of PAH. We report that human PAEC with reduced BMPR2 have persistent DNA damage in room air after hypoxia (reoxygenation), as do mice with EC-specific deletion of Bmpr2 (EC-Bmpr2
Indexed as
Hypertension, PulmonaryPulmonary Arterial HypertensionAnimalsBone Morphogenetic Protein Receptors, Type IIDNA DamageFamilial Primary Pulmonary HypertensionForkhead Transcription FactorsHumansMicePulmonary ArteryBone Morphogenetic Protein Receptors, Type IIForkhead Transcription FactorsFOXF1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.